Rationale:
Severe asymptomatic organic Mitral Valve (MV) regurgitation with preserved left ventricular (LV) function is a challenging clinical entity as data on the recommended treatment strategy for these patients are scarce and conflicting, which is reflected in current guidelines. European guidelines advocate a more conservative strategy i.e. watchful waiting, with yearly echocardiography, whilst American guidelines are more in favour of early surgery to reconstruct the MV, i.e. MV repair (in contrast to MV replacement) in order to prevent future LV dysfunction and complaints.
A number of non-randomised trials show a favourable outcome of early surgery: in the study of Enriquez-Sarano et al. for instance, the early surgery strategy has shown to be associated with improved long-term survival, decreased cardiac mortality, and decreased morbidity compared with the conservative management [1]. On the other hand, non-randomised trials describe also that a conservative strategy (i.e. watchful waiting) can be safely accomplished. If facilitated surgery is performed in this population (50% at 10 years follow-up according to Rosenhek et al [2]), it has proven to be eventually associated with good perioperative and postoperative outcome when careful follow-up is being carried out [2].
Objective:
To compare early MV repair versus watchful waiting in asymptomatic patients with severe organic mitral valve regurgitation and preserved left ventricular function.
Study design:
Multicenter, registry trial.
Study population:
250 Asymptomatic patients (18-75 years old) with severe organic MV regurgitation and preserved left ventricular function. The current European Society of Cardiology (ESC) guidelines on Valvular Heart Disease will be applied [3]. These guidelines are also used in the Netherlands. Accordingly, patients with an indication for MV surgery will not be included.
Intervention:
Intervention will be early MV repair compared to a watchful waiting strategy.
Condition or disease | Intervention/treatment |
---|---|
Mitral Regurgitation | Procedure: Mitral valve repair |
Study Type : | Observational [Patient Registry] |
Estimated Enrollment : | 500 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Target Follow-Up Duration: | 5 Years |
Official Title: | Dutch-AMR Study: Early Mitral Valve Repair Versus Watchful Waiting in Asymptomatic Patients With Severe Organic Mitral Regurgitation and Preserved Ejection Fraction: a Multicenter Registry Trial |
Study Start Date : | October 2016 |
Estimated Primary Completion Date : | October 2026 |
Estimated Study Completion Date : | October 2031 |
Group/Cohort | Intervention/treatment |
---|---|
Aymptomatic patients with severe mitral regurgitation
Watchful waiting Early Surgery
|
Procedure: Mitral valve repair
Minimally invasive repair of severe organic mitral regurgiation
|
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
Exclusion Criteria:
Netherlands | |
Amsterdam Medical Center (AMC) | Recruiting |
Amsterdam, Netherlands | |
Contact: Matthijs Boekholdt s.m.boekholdt@amsterdamumc.nl | |
Sub-Investigator: Jolanda Kluin | |
Principal Investigator: Matthijs Boekholdt | |
Sub-Investigator: Rene van den Brink | |
Amphia Breda | Recruiting |
Breda, Netherlands | |
Contact: Jeroen Schaap jschaap@amphia.nl | |
Principal Investigator: Jeroen Schaap, MD | |
Medisch Spectrum Twente (MST) | Recruiting |
Enschede, Netherlands | |
Contact: Lodewijk Wagenaar L.Wagenaar@mst.nl | |
Principal Investigator: Lodewijk Wagenaar | |
Leiden University Medical Center (LUMC) | Active, not recruiting |
Leiden, Netherlands | |
Maastricht UMC | Recruiting |
Maastricht, Netherlands | |
Contact: Bas Streukens bas.streukens@mumc.nl | |
University Medical Center Utrecht (UMC Utrecht) | Recruiting |
Utrecht, Netherlands, 3584 CX | |
Contact: Steven AJ Chamuleau, MD, PhD 0031 88 75 59801 S.A.J.Chamuleau@umcutrecht.nl | |
Principal Investigator: Steven AJ Chamuleau, MD, PhD | |
Sub-Investigator: Einar A Hart, MD | |
Sub-Investigator: Maarten Jan M Cramer, MD, PhD |
Tracking Information | |||
---|---|---|---|
First Submitted Date | November 28, 2016 | ||
First Posted Date | June 5, 2019 | ||
Last Update Posted Date | June 6, 2019 | ||
Study Start Date | October 2016 | ||
Estimated Primary Completion Date | October 2026 (Final data collection date for primary outcome measure) | ||
Current Primary Outcome Measures |
Time to event: cardiovascular mortality, congestive heart failure, hospitalization, class I or class IIa indication for MV surgery [ Time Frame: 5 years ] | ||
Original Primary Outcome Measures | Same as current | ||
Change History | |||
Current Secondary Outcome Measures | Not Provided | ||
Original Secondary Outcome Measures | Not Provided | ||
Current Other Pre-specified Outcome Measures | Not Provided | ||
Original Other Pre-specified Outcome Measures | Not Provided | ||
Descriptive Information | |||
Brief Title | Dutch-AMR: Early Mitral Valve Repair Versus Watchful Waiting in Asymptomatic Patients With Severe Mitral Regurgitation | ||
Official Title | Dutch-AMR Study: Early Mitral Valve Repair Versus Watchful Waiting in Asymptomatic Patients With Severe Organic Mitral Regurgitation and Preserved Ejection Fraction: a Multicenter Registry Trial | ||
Brief Summary |
Rationale: Severe asymptomatic organic Mitral Valve (MV) regurgitation with preserved left ventricular (LV) function is a challenging clinical entity as data on the recommended treatment strategy for these patients are scarce and conflicting, which is reflected in current guidelines. European guidelines advocate a more conservative strategy i.e. watchful waiting, with yearly echocardiography, whilst American guidelines are more in favour of early surgery to reconstruct the MV, i.e. MV repair (in contrast to MV replacement) in order to prevent future LV dysfunction and complaints. A number of non-randomised trials show a favourable outcome of early surgery: in the study of Enriquez-Sarano et al. for instance, the early surgery strategy has shown to be associated with improved long-term survival, decreased cardiac mortality, and decreased morbidity compared with the conservative management [1]. On the other hand, non-randomised trials describe also that a conservative strategy (i.e. watchful waiting) can be safely accomplished. If facilitated surgery is performed in this population (50% at 10 years follow-up according to Rosenhek et al [2]), it has proven to be eventually associated with good perioperative and postoperative outcome when careful follow-up is being carried out [2]. Objective: To compare early MV repair versus watchful waiting in asymptomatic patients with severe organic mitral valve regurgitation and preserved left ventricular function. Study design: Multicenter, registry trial. Study population: 250 Asymptomatic patients (18-75 years old) with severe organic MV regurgitation and preserved left ventricular function. The current European Society of Cardiology (ESC) guidelines on Valvular Heart Disease will be applied [3]. These guidelines are also used in the Netherlands. Accordingly, patients with an indication for MV surgery will not be included. Intervention: Intervention will be early MV repair compared to a watchful waiting strategy. |
||
Detailed Description | Not Provided | ||
Study Type | Observational [Patient Registry] | ||
Study Design | Observational Model: Cohort Time Perspective: Prospective |
||
Target Follow-Up Duration | 5 Years | ||
Biospecimen | Not Provided | ||
Sampling Method | Non-Probability Sample | ||
Study Population | Asymptomatic patients with severe organic mitral regurgitation and preserved ejection fraction. | ||
Condition | Mitral Regurgitation | ||
Intervention | Procedure: Mitral valve repair
Minimally invasive repair of severe organic mitral regurgiation
|
||
Study Groups/Cohorts | Aymptomatic patients with severe mitral regurgitation
Watchful waiting Early Surgery
Intervention: Procedure: Mitral valve repair
|
||
Publications * |
|
||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||
Recruitment Information | |||
Recruitment Status | Recruiting | ||
Estimated Enrollment |
500 | ||
Original Estimated Enrollment | Same as current | ||
Estimated Study Completion Date | October 2031 | ||
Estimated Primary Completion Date | October 2026 (Final data collection date for primary outcome measure) | ||
Eligibility Criteria |
Inclusion Criteria:
Exclusion Criteria:
|
||
Sex/Gender |
|
||
Ages | 18 Years to 75 Years (Adult, Older Adult) | ||
Accepts Healthy Volunteers | No | ||
Contacts | |||
Listed Location Countries | Netherlands | ||
Removed Location Countries | |||
Administrative Information | |||
NCT Number | NCT03975998 | ||
Other Study ID Numbers | 16/743 | ||
Has Data Monitoring Committee | No | ||
U.S. FDA-regulated Product | Not Provided | ||
IPD Sharing Statement |
|
||
Responsible Party | S.A.J. Chamuleau, UMC Utrecht | ||
Study Sponsor | UMC Utrecht | ||
Collaborators |
|
||
Investigators | Not Provided | ||
PRS Account | UMC Utrecht | ||
Verification Date | June 2019 |